TEL AVIV, Israel, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that the Company will provide a corporate overview at two upcoming investor conferences in November.
|
Credit Suisse Healthcare Conference |
|
|
Date: |
November 12 |
|
Time: |
7:30AM MST |
|
Location: |
Arizona Biltmore Hotel, Scottsdale, Arizona |
|
|
|
|
Stifel Annual Healthcare Conference |
|
|
Date: |
November 18 |
|
Time: |
9:10AM Eastern |
|
Location: |
New York Palace Hotel |
|
Webcast: |
http://www.alcobra-pharma.com/events.cfm |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed multiple Phase II studies and one Phase III study in adults with ADHD. The company is conducting separate Phase IIb trials in pediatric ADHD and Fragile X Syndrome. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
CONTACT: U.S. Investor Contacts
LifeSci Advisors, LLC
Michael Rice
646-597-6979
mrice@lifesciadvisors.com
Media Inquiries
Sam Brown, Inc.
Mike Beyer
773-463-4211
mikebeyer@sambrown.com
Israel Investor Contact:
Alcobra Investor Relations
Debbie Kaye
+972-72 2204661
debbie@alcobra-pharma.com
